Caspases are a family of cysteine proteases that play important roles in regulating apoptosis. A decade of research has generated a wealth of information on the signal transduction pathways mediated by caspases, the distinct functions of individual caspases and the mechanisms by which caspases mediate apoptosis and a variety of physiological and pathological processes.
mentation, phosphatidylserine exposure and, finally, fragmentation into membrane-enclosed apoptotic bodies sequestered by macrophages or other engulfing cells (Wyllie et al., 1980) . Apoptosis is critical for the maintenance of normal homeostasis, on par with other important processes like proliferation and differentiation. The dysregulation of such a powerful process can lead to disastrous consequences, and is involved in many diseases such as cancer, autoimmunity and neurodegeneration.
The central components of PCD machine in C. elegans are a troika of ced genes: ced-3, ced-4 and ced-9, where ced-9 protein is an inhibitor of apoptosis, ced-4 protein is a proapoptotic adaptor molecule and ced-3 protein is a cysteine protease responsible for the execution of the apoptotic program (Hengartner et al., 1992; Yuan and Horvitz, 1992; Yuan et al., 1993) . Homologues of these genes have been clearly shown to regulate apoptosis in higher eukaryotes, albeit utilizing much more evolved and complex mechanisms. The mammalian homologues of ced-9, the Bcl-2 family members, are critical regulators of the mitochondrial step in apoptosis . Apaf-1, a mammalian ced-4 homologue , is a regulator of the postmitochondrial, cytochrome-c-dependent step (Budihardjo et al., 1999) . Finally, a large family of cysteine proteases, termed caspases, is responsible for the execution of apoptosis in a multitude of higher eucaryotes (Cryns and Yuan, 1998) .
This year is the 10th anniversary of the discovery of the critical role of caspases in apoptosis (Miura et al., 1993; Yuan et al., 1993) . In this review, we will summarize the current knowledge of this protease family in apoptosis and other physiological and pathological processes.
General features and classification of caspases
The history of caspases began with the discovery that the C. elegans ced-3 gene encodes a homologue of the independently identified human interleukin-1b processing enzyme (ICE) (Cerretti et al., 1992; Thornberry et al., 1992) . The subsequent demonstration that overexpression of ICE (renamed caspase-1) in mammalian cells is sufficient to induce apoptosis suggested that caspases may play a role analogous to that of ced-3 in mammalian PCD (Miura et al., 1993) . The demonstration that the expression of a caspase inhibitor protein in sensory neurons prevented neuronal cell death induced by trophic factor deprivation provided the first evidence for a functional role of caspases in neuronal cell death (Gagliardini et al., 1994) . Finally, a member of the caspase family, caspase-3, was shown to be a critical mediator of the endogenous apoptotic pathway in mammalian cells . The identification of caspases in C. elegans, Drosophila and all studied vertebrate species demonstrated the evolutionary conservation of apoptotic machinery.
Currently, 11 human caspases have been identified: caspase-1-10 and caspase-14 Pistritto et al., 2002) . The protein initially named caspase-13 was later found to represent a bovine homologue of caspase-4 (Koenig et al., 2001) , and caspase-11 and -12 are murine enzymes that are most likely the homologues of human caspase-4 and -5 (see below). There is a clear evolutionary tendency to increase the number of caspases over phylogenetic time, from four in C. elegans to seven in Drosophila and 11 in mice and humans (Lamkanfi et al., 2002) .
All caspases share a number of distinct features. These include the catalytic triad residues, consisting of the active site Cys285, which is a part of the conserved QACXG pentapeptide sequence, His237 and the backbone carbonyl of residue 177 (caspase-1 numbering) . A striking feature of the caspase family is its specificity for substrate cleavage after an Asp residue, which is unique among mammalian proteases, except for the serine protease granzyme B (see below). All caspases are synthesized as inactive zymogens containing a prodomain followed by p20 large and p17 small subunits (Figure 1b) . The activation of the zymogen precursor is mediated by a series of cleavage events, first separating the large and small subunits, followed by the removal of the prodomain (Figure 2c ) (Ramage et al., 1995; Yamin et al., 1996) .
Multiple rubrics have been used to classify caspases but, interestingly, all methods result in similar groupings, suggesting tight structure-function correlations within the caspase family. The first classification method is based on caspase function. During apoptosis, uniform execution machinery is triggered by a wide variety of extra-and intracellular signals. Therefore, some caspases have evolved to link distinct upstream signaling pathways with the downstream execution steps. These upstream family members are termed 'initiator' caspases ( Figure 1a ). Initiator caspases possess long prodomains containing one of two characteristic protein-protein interaction motifs: the death effector domain (DED) (caspase-8 and -10) and the caspase activation and recruitment domain (CARD) (caspase-1, -2, -4, -5, -9, -11 and -12) (Figure 1b) , providing the basis for interaction with upstream adaptor molecules. Among the initiator caspases, caspase-1, -11 and -5 form a subclass of caspases that controls both apoptosis and certain inflammatory responses. On the other hand, caspases that perform the downstream execution steps of apoptosis by cleaving multiple cellular substrates are typically processed and activated by upstream caspases. The downstream caspases form an 'executioner' class (caspase-3, -6, -7) and are characterized by the presence of a short prodomain.
Protease families can be also classified according to their substrate preferences. Thornberry and co-workers developed a combinatorial method to assess caspase substrate specificity in vitro using peptide-aminomethylcoumarin (AMC) substrates . Using this approach, the preferred tetrapeptide substrates for caspase-1-11 were determined Kang et al., 2000) (Figure 1c ). Caspases separate into three classes based on the identity of the residue in the P4 position of the substrate, which is a primary determinant of specificity. The first group, which includes caspase-1, -4 and -5, prefers bulky, hydrophobic side chains in the P4 substrate position, with the optimal sequence of WEHD (class I). The second class, consisting of caspase-6, -8, -9 and -11, has a preference for (L/V)EXD (class II). Finally, the optimal sequence for the third class, consisting of caspase-2, -3 and -7 is DEXD, where X is V, T or H (class III) (Figure 1c ). Thornberry et al. (1997) . Preferred amino acids in P4-P1 positions are shown. Based on the size of the S4 subsite and P4 residue, caspases can be divided into three subfamilies. (d) Initial processing site sequences in caspases. Note that they fit the preferred sequence for the initiator subfamily
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A Degterev et al Such analysis on caspase-10 and -12 has not been published. Several observations can be made based on this substrate specificity classification. First, with the exception of caspase-2 and -6, this classification is also consistent with the above-mentioned functional subdivisions of the family (Figure 1a) . The substrate preferences of caspase-11 are most similar to the initiator group II, consistent with the observation that this caspase can initiate apoptosis through direct cleavage of caspase-3 (see below) (Kang et al., 2000) in addition to its role in inflammation. Second, these substrate preferences fit well with the sites found in the known preferred in vivo substrates of each functional class (Figure 1a ), such as IL-1b and IL-18 (dual role initiator class), laminin A, caspase-3 and -7 (apoptotic initiator class), and PARP and DNA-PK (effector class) . Most strikingly, the initial, most important (see below) processing sites between the large and small subunits in all initiator caspases conform to their own substrate preferences (Figure 1d) , consistent with the ability of the initiator caspases to activate themselves, whereas processing sites in effector caspases fit the preferences of the class II caspases, consistent with being downstream activation targets of initiator caspases (see below). Interestingly, caspase-2 exhibits features of both an initiator caspase as well as an executioner caspase: the presence of a CARD domain in caspase-2 suggests its initiator role; however, both the substrate preference and the cleavage site between the large and small subunits of caspase-2 are similar to that of the executioner caspases, that is, DXXD. Such characteristics of caspase-2 suggest that it may act as a proximal responder to auto-activate in apoptosis signaling under certain conditions (Lassus et al., 2002; Paroni et al., 2002; Robertson et al., 2002) as well as function as an executioner caspase by cleaving cellular targets, rather than activating downstream caspases.
The substrate specificity studies provide interesting data that may help explain the differences in the physiological roles of individual caspases, but as these results were derived using a short synthetic substrate in vitro, they should be interpreted with caution. Caspases may require cofactors in vivo, such as the apoptosome complex in the case of caspase-9, which may control the efficiency of catalysis as well as substrate specificity (Rodriguez and Lazebnik, 1999) . Therefore, results obtained in vitro using purified recombinant proteins may not accurately reflect the enzymatic potential of the 'native' cellular protein. It should also be kept in mind that the in vitro results primarily show sites preferentially recognized by a particular caspase. They do not take into account intrinsic differences in caspases 0 ) (reproduced from Shi, 2002) based on the crystal structure of the complex of caspase-3 with Ac-DVAD-fmk (Mittl et al., 1997) . The inhibitor is shown in purple. (B) The active site conformations of the caspases with known structures (1, 3, 7, 8 and 9) . Loops L1 and L3 are highly conserved, whereas L2 and L4 are primarily responsible for the differences in substrate specificity. Reproduced from Shi (2002) . (C) Generalized distribution of caspase catalytic center loops (L1-L4) on small and large subunits. Loops are shown in blue. Position of the activating cleavage processing are shown by arrows. Numbers represent the order of the activation cleavages. The active site Cys is shown by a red asterisk. Processing occurs in L2. The resulting large subunit portion of the L2 loop of one monomer and small subunit portion of the L2 loop of another monomer (L2 0 ) are involved in loop bundle formation (a, b) . (D) Interactions in the active sites of caspases based on the crystal structures of active caspase-1, -3, -7 and -8 with DEVD-CHO (reproduced from Wei et al., 2000) activity or local concentration, which may result in some caspase cleaving its 'nonoptimal' substrate at a higher rate than another, less active caspase, which nevertheless prefers that site more strongly. Therefore, the in vitro data may not accurately point to the preferred caspase family member cleaving the particular substrate. Therefore, substrate recognition may primarily serve to provide the optimal kinetics for regulating sequential events in caspase cascades during apoptosis.
Caspase structure and enzymatic mechanism
The structures of active caspase-1, -3, -7, -8 and -9 have been solved, providing valuable insights into the basis of caspase specificity and catalytic mechanisms (Walker et al., 1994; Wilson et al., 1994; Rotonda et al., 1996; Mittl et al., 1997; Blanchard et al., 1999; Watt et al., 1999; Wei et al., 2000; Renatus et al., 2001) . The active caspase is a homodimer, with each monomer consisting of a large and a small subunit (Figure 2a ). Six antiparallel b strands of each monomer form a continuous 12-stranded b sheet in the active enzyme with a separate active center formed by each monomer symmetrically located on the opposite sides of the enzyme (Figure 2a ). This topology is different for caspase-9, in which case only one active center is formed (Renatus et al., 2001) .
Caspase substrate specificity is predominantly determined by the four amino-acid residues N-terminal to the scissile bond (P4-P1) (Margolin et al., 1997) . The caspase cleavage mechanism is based on the catalytic triad composed of Cys285, His237 and the carbonyl of residue 177, which is somewhat unusual, since the side chain of the residue 177 does not appear to play a role . In addition, an oxyanion hole consisting of Gly238 and Cys285 also contributes to the catalysis.
The entire active center of caspases, consisting of the S4-S3-S2-S1 specificity subsites binding P4-P3-P2-P1 residues of the substrate, respectively, is formed by flexible loops (L1-L4) (Figures 2a-c) (Shi, 2002) . Loop L1 and a portion of L2, which contains the catalytic Cys residue, are a part of the large subunit, whereas L3 and L4 come from the small subunit (Figure 2a, c) . The activation-mediated cleavage of caspases occurs in the loop L2, liberating the C-terminus of the large and the N-terminus of the small subunits (Figure 2c ). The size and topology of the L1 and L3 loops are highly conserved among various caspases, whereas the L2 and L4 loops display a greater degree of variation (Figures 2b) . The S1 subsite in all caspases is formed by the L1, L2 and L3 loops and is very narrow and deep. The restrictive geometry of the S1-binding pocket limits P1 residue to Asp, providing the molecular basis for the distinctive specificity of the caspase family. The sidechain of the Asp substrate residue is coordinated by three invariant residues (Arg179, Gln283 and Arg341, caspase-1 numbering) (Figure 2d ). Since the P2 side chain is facing the outside of the active center, there is a greater degree of variation in the identity of the amino acid accepted in this position . At P3, Glu is preferred by all caspases due to its interaction with the surface-exposed Arg341 and, in the case of caspase-8, also with Arg177 (Blanchard et al., 1999) (Figure 2d ). This interaction is predicted to contribute to the proper positioning of the substrate . Additional residues (Ser239 and Arg341) coordinate the amino and carbonyl groups of the amide bonds formed by P1 and P3 (Figure 2d) .
Whereas the S1 subsite interaction distinguishes the caspase family from other proteases (Barrett and Rawlings, 2001) , the selectivity of different caspases is generated by the S4 subsite, formed by the L4 loop of the small subunit (Shi, 2002; Thornberry et al., 1997) . A comparison of the L4 loops from the available caspase structures shows that caspase-3 and -7 have the largest loops, followed by caspase-8 and -9 and then caspase-1 (Figures 2b). In addition, the crystal structures of the complexes of caspase-1, -3, -7 and -8 with Ac-DEVD-CHO show that caspase-1 forms the lowest number of hydrogen bonds with the P4 Asp residue and possesses the smallest (Val versus Trp for caspase-3, -7 and -8) residue at the bottom of the S4 pocket (Figures 2d). All of these factors contribute to caspase-1 having the widest S4-binding site, which favors large hydrophobic residues. In contrast, caspase-3 and -7 possess the narrowest pocket, which, along with an extensive hydrogen bonding pattern (Figure 2d ), creates a preference for the Asp residue in the P4 position Wei et al., 2000) . The S4 pockets of caspase-8 and -9 occupy intermediate positions and show preference for small hydrophobic Val or Leu . However, caspase-8 also efficiently recognizes the class II substrate DEVD . A comparison of the available data also shows that the major structural differences among the caspases are localized to the active sites, with the rest of the backbone being quite similar .
The use of extended caspase substrates demonstrated a surprising selectivity of the family for residues in the P1 0 position . Whereas small (Gly, Ser and Ala) and large aromatic (Phe and Tyr) amino acids are well tolerated, charged amino acids are completely prohibited.
In addition to the above-mentioned structural determinants governing caspase substrate specificity, the executioner caspase-3, -6 and -7 also possess a nineamino-acid insertion following residue 381, which is absent in caspase-1 and -8 . This loop is postulated to block sterically the entry of inappropriate substrates into the active sites of the executioner caspases, as exemplified by the cowpox caspase-inhibitory protein CrmA (see below) .
Cellular pathways controlling caspase activation
As active caspases can cause rapid cell death, there is a need for stringent mechanisms to control caspase
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The apoptotic signaling pathways that lead to caspase zymogen processing can be subdivided into two major categories: cell surface sensor-mediated and intracellular sensor-mediated. The former pathway is activated in response to extracellular signals, indicating that the cell's existence is no longer needed for the well-being of the organism. Cell surface sensor-directed apoptotic signals are initiated by ligands binding to cell surface death-mediating receptors and are exemplified by the signaling of the death receptor family.
The death receptor family, including CD95/Fas/ Apo1, TNFR1, TNFR2, DR3/Wsl-1/Tramp, DR4/ TRAIL-R1, DR5/TRAIL-R2/TRICK2/Killer and DR6 (see review on this topic in this issue) is characterized by the presence of multiple cysteine-rich repeats in the extracellular portion and the proteinprotein interaction module known as the death domain (DD) in the cytoplasmic tails. Ligand-induced receptor multimerization results in the formation of the death inducing signaling complex (DISC) containing multiple adaptor molecules, including FADD (Fas associated DD), TRADD (TNF receptor associated DD), DAXX, RIP (receptor interacting protein kinase), RAIDD (RIP associated protein with a DD) and FLIP (FLICE-like inhibitory protein) (see review on this topic in this issue of Oncogene). FADD, which is recruited to the DISC through its C-terminal DD, interacts through its Nterminal DED with the DED of caspase-8 (Muzio et al., 1996;  Figure 3 ). The recruitment and oligomerization of caspase-8 in the DISC results in its autocatalytic activation (see below) and is critical for the initiation of cell death (Juo et al., 1998; Varfolomeev et al., 1998) . Caspase-10 and -2 may also be recruited to and activated at the DISC, but their role in death receptor signaling remains controversial (Kischkel et al., 2001; Wang et al., 2001; Sprick et al., 2002) .
How does the activation of caspase-8 lead to cell death? The most direct pathway, present in the so-called type I cells, involves the processing and activation of the executioner caspase-3 and -7 by caspase-8 (Scaffidi et al., 1998) (Figure 3 ). These latter caspases execute apoptosis by cleaving various cellular substrates (see below), including other caspases, leading to the branched cascades of caspase activation (Hirata et al., 1998) . The existence of such caspase cascades, which serve to amplify apoptotic signaling, may be necessary because of the inability of the initiator caspases to complete the execution of apoptosis on their own. In addition, such pathways may enable cells to maintain a tighter control over the cellular suicide mechanism at multiple points.
As noted, the above mechanism for receptor-induced apoptosis is present only in type I cells, which are capable of producing a sufficient amount of activated caspase-8 to activate enough downstream caspases to complete apoptosis (Scaffidi et al., 1998) . In contrast, in the so-called type II cells, death receptor apoptotic signaling depends on a mitochondrial amplification step (Figure 3 ), which may be necessary because of an insufficient amount of active caspase-8 or downstream caspases. In the type II pathway, caspase-8 cleaves the cytosolic BH3-only proapoptotic Bcl-2 family member Bid Luo et al., 1998) . The processing of Bid results in its translocation to mitochondria, where it causes cytochrome c release through oligomerization of the proapoptotic Bcl-2 family members Bax and Bak (Korsmeyer et al., 2000) (Figure 3 ). Released cytochrome c induces the formation of the apoptosome complex in the cytosol (Figure 3) . The apoptosome, which was initially defined by the works of Wang and co-workers (Liu et al., 1996; Li et al., 1997c; Zou et al., 1997) , was shown to be a heptamer comprised of seven Apaf-1 adaptor molecules, each bound to one molecule of cytochrome c and a dimer of the initiator caspase-9 (Cain et al., 2000; Acehan et al., 2002) . Caspase-9, which is activated through an apoptosome-induced conformational change (see below), also processes the executioner caspase-3 and -7 to initiate the execution of apoptosis in a manner similar to that of caspase-8 (Li et al., 1997c; Slee et al., 1999) (Figure 3) . The other major category of apoptotic signaling, the intracellular sensor-mediated pathway, is activated by stimuli such as DNA damage and cytotoxic drugs, which act inside the cell, and is very similar to the type II death receptor mechanism in its requirement for signal amplification through mitochondrial damage. Cells possess multiple means of targeting mitochondria, but most of these signals integrate at the level of the Bax/ Bak gateway (see review on Bcl-2 family in this issue of Oncogene) (Figure 3 ).
An important issue with respect to apoptosis signaling pathways is the timing of the 'point-of-no-return'. This event is defined as the step in the signaling process after which termination of the apoptosis-inducing stimuli does not prevent the execution of apoptosis. Elegant studies with nerve growth factor (NGF) deprivationmediated apoptosis of sympathetic neurons suggested that the 'point-of-no-return' occurs downstream of cytochrome c release and coincides with executioner caspase activation, whereas the inhibition of caspase activity delays the commitment to death until mitochondrial depolarization (Deshmukh et al., 2000) . The latter mechanism was further addressed by the analyses of the effect of cytochrome c readdition on the Fas-mediated loss of mitochondrial function (Mootha et al., 2001 ) and single cell analyses of mitochondrial respiratory function following apoptotic induction by UV/cytotoxic drugs (Waterhouse et al., 2001) . These studies suggested that, apart from caspase activation, cytochrome c release causes slow acquisition of the irreversible loss of mitochondrial function and respiration, which may lead to death. Therefore, the mitochondrial apoptotic pathway appears to result in a bipartite 'point-of-noreturn' event, consisting of fast caspase activation and slow, caspase-independent death through mitochondrial dysfunction.
Since caspase-1, -5 and -11 form a separate subfamily with a dual role in regulating both cytokine processing and inflammatory signaling as well as apoptosis, they are involved in unique activation networks. Mouse genetic knockout studies have clearly shown that caspase-11 mediates the activation of caspase-1, which in turn processes cytokines IL-1b and IL-18 Ghayur et al., 1997; Wang et al., 1998) . In the case of human cells, lipopolysaccharide (LPS) induces the expression of caspase-5, like that of caspase-11 in murine cells (Lin et al., 2000) , and caspase-5 was recently shown to be involved in the activation of human caspase-1 as a part of an 'inflammasome' complex, which also includes the adaptor molecules NALP1 and Pycard (Martinon et al., 2002) . Based on these similarities, human caspase-5 is most likely a functional human homologue of murine caspase-11. As for the induction of apoptosis, caspase-11 has been demonstrated to process caspase-3 directly during ischemia and septic shock in addition to regulating caspase-1 activation (Kang et al., 2000 . The activation of caspase-3 by caspase-11 is directly responsible for the apoptosis of lymphocytes during septic shock and, consistent with this conclusion, a novel nonpeptide inhibitor of caspase-3 was found to decrease mortality and bacteremia in vivo following LPS injection, most likely by preventing the lymphocyte loss due to apoptosis (Hotchkiss et al., 2000) .
In addition to the above-mentioned caspase-dependent pathways, multiple noncaspase proteases were also shown to process and activate caspases directly. For example, granzyme B, a unique serine protease with substrate specificity for aspartate residues, is critical for the killing of virally infected cells by cytotoxic lymphocytes (CTL) and directly activates caspase-3 in target cells (Darmon et al., 1995) . The Ca 2 þ -activated protease m-calpain can process caspase-12 following ER stress , whereas the lysosomal protease cathepsin B was shown to process caspase-1 and -11 in vitro (Schotte et al., 1998; Vancompernolle et al., 1998) . In summary, cells possess diverse arrays of caspase activation cascades, which control the activation of specific caspase groups in response to a variety of cytotoxic and inflammatory stimuli.
Functions of individual caspases
Our current knowledge suggests that the expansion of the caspase family in higher organisms may reflect a need to increase the specialization of cellular signaling in apoptosis. Here, we will summarize our current knowledge of the specific roles of individual caspases, with special emphasis on the lessons learned from mouse knockout studies.
Caspase-1, -11 and -5
Caspase-1 and -11-deficient mice provided clear insights into their specific and nonredundant functions. The deletion of caspase-1 showed no ill effects on animal development, and embryonic fibroblasts and thymocytes isolated from these mice displayed full sensitivity to various apoptotic stimuli Smith et al., 1997) (Table 1) . Caspase-1À/À mice, however, showed specific defects in processing and secretion of the proinflammatory cytokines IL-1b and IL-18 and were resistant to LPS-induced septic shock (Kuida et al., 1995; Li et al., 1995; Ghayur et al., 1997) , which is consistent with caspase-1's original identification as an IL-1b processing enzyme (Cerretti et al., 1992; Thornberry et al., 1992) . For as yet unknown reasons, IL-1a secretion, but not processing, is also prevented in the absence of caspase-1 (Kuida et al., 1995; Li et al., 1995) .
Interestingly, even though caspase-1 is most likely a downstream target of caspase-11 (see below) , the two published lines of caspase-1 knockout mice cannot be induced to express caspase-11 (Kang et al., 2000) . Thus, although caspase-1 most likely is directly involved in the processing of IL-1b in vivo, the null phenotype of this caspase is still far from clear.
The expression of an active site mutant caspase-1 in a transgenic mouse inhibited IL-1b secretion, similar to the knockout results, and neurons from these mice were partially resistant to trophic factor deprivation-induced cell death in vitro and ischemic brain damage in vivo Decade of caspases A Degterev et al (Friedlander et al., 1997b; Hara et al., 1997) . Interestingly, these mice also displayed a delayed onset of motor dysfunction when crossed with a transgenic mouse expressing mutant SOD, a mouse model of amyotrophic lateral sclerosis (ALS) (Friedlander et al., 1997a) . The targets of this caspase-1 mutant, however, remain unclear as caspase-1 can interact and potentially interfere with other caspases, such as caspase-11 . Therefore, these promising data should be considered with caution. Murine caspase-11 displays a high degree of homology with caspase-1. Caspase-11À/À mice are developmentally normal, but are resistant to endotoxic shock and lack caspase-1 activation and IL-1b secretion, although caspase-11 does not directly process pro-IL1b (Table 1) . These data clearly demonstrate that caspase-11 plays a critical role in the activation of caspase-1. Caspase-11 and its human orthologue caspase-5 have been shown to form a complex with caspase-1, which may be a critical step in mediating the activation of caspase-1 Martinon et al., 2002) . However, there is no in vitro or in vivo evidence that caspase-11 or -5 activates caspase-1 through direct proteolytic cleavage. In contrast, caspase-11 activates caspase-3 by direct proteolytic cleavage in mediating apoptosis following septic shock and brain ischemia (Kang et al., 2000 .
Caspase-2
Caspase-2 may be the most tantalizing member of the family (Wang et al., 1994) . Its long, CARD-containing prodomain, its early activation in response to a variety of apoptotic stimuli (Harvey et al., 1997) and its RAIDD-mediated interaction with Fas in overexpression systems (Ahmad et al., 1997; Duan and Dixit, 1997) suggest its role as an initiator caspase. On the other hand, it may be activated by downstream executioner caspases such as caspase-3 (Li et al., 1997a) and its substrate preferences also belong to the effector class ( Figure 2c ). One interesting feature of caspase-2 is its intracellular localization to nuclei and the Golgi (Colussi et al., 1998; Mancini et al., 2000) . Its nuclear import is mediated by two nuclear localization signals (NLSs) present in the prodomain, but the significance of the nuclear pool of caspase-2 is currently unclear, since overexpression of the cytosolic form of caspase-2 with a mutated NLS is fully capable of inducing apoptosis (Colussi et al., 1998; Baliga et al., 2002) . In the Golgi, caspase-2 may contribute to the fragmentation of this organelle associated with apoptosis through the cleavage structural protein golgin-160 (Mancini et al., 2000) . Therefore, caspase-2 may contribute to organellespecific apoptotic events. However, these results were obtained using overexpression systems and therefore, the precise contribution of these caspase-2-mediated events to the grand scheme of apoptosis remains to be confirmed in future.
The use of antisense constructs to inhibit the expression of caspase-2 demonstrated its prominent role in several in vitro cell death model systems, including neurotrophic factor deprivation of sympathetic neurons, Ab-induced apoptosis in hippocampal neurons and Fasmediated death of lymphocytes (Haviv et al., 1998; Stefanis et al., 1998; Troy et al., 2000) . However, caspase-2À/À mice are viable and caspase-2À/À cells show normal induction of apoptosis in response to multiple stimuli (Bergeron et al., 1998) ( Table 1 ). The only observed apoptotic defects in these mice are excessive germ cells in the ovaries of female mutant mice, the resistance of oocytes to chemotherapeutic drug-induced apoptosis and the reduced death of lymphocytes treated with granzyme B (Bergeron et al., 1998) . The lack of global neuron-specific apoptotic defects in caspase-2-deficient mice may be explained by compensation mechanisms, as suggested by a recent study by Troy et al. (2001) , which showed that the caspase-9 pathway may take over the functions of caspase-2 in caspase-2À/À sympathetic neurons.
One novel approach, which may allow analysis of the protein cellular function without the limitations of possible genetic compensation triggered in transgenic approaches, is the use of short interfering RNA molecules (RNAi) to downregulate endogenous protein expression levels (Hunter, 1999; Sharp, 1999) . This method indeed has recently been very successfully utilized for caspase-2, demonstrating the critical role of caspase-2 in genotoxic stress-mediated cell death in cultured cells (Lassus et al., 2002) . Therefore, unlike transgenic mice, RNAi may help elucidate the true role of caspase-2 in various apoptotic systems.
Interestingly, caspase-2 knockout mice also showed fewer facial motor neurons at birth, which became normal by day 7 (Bergeron et al., 1998) . This defect may reflect in vivo antiapoptotic function of the short splice variants of caspase-2, which were previously shown to inhibit apoptosis in vitro (Wang et al., 1994) .
Several recent studies suggested that, rather than activating downstream caspase networks, as other initiator caspases, caspase-2 may act primarily on noncaspase substrates to mediate cell death. In that respect, caspase-2 was found to cause the release of apoptogenic factors from mitochondria directly, a process which may be mediated in part by caspase-2 cleavage of Bid (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002) . Overall, these findings suggest that caspase-2 has many properties distinct from other caspases, but we still have very little knowledge regarding its true role in cell death in vivo.
Caspase-12
Murine caspase-12 localizes specifically to the ER, which is unique among caspases . Caspase-12-deficient mice are developmentally normal (Table 1) ; however, caspase-12 deletion renders cells specifically resistant to ER stress-induced cell death in vitro and in vivo, consistent with its subcellular localization . These data suggest that caspase-12 is a specific sensor of ER perturbation. Ab cytotoxicity is also attenuated in caspase-12À/À cortical neurons, providing evidence for a role of ER stress in Alzheimer's disease (AD) .
Although functional data clearly place caspase-12 in the center of ER stress-mediated death, the pathways upstream and downstream of caspase-12 still remain to be characterized. Thus far, calpain and caspase-7 have been proposed to activate caspase-12 Rao et al., 2001) , whereas caspase-12 was proposed to mediate cytochrome c-independent activation of caspase-9 (Morishima et al., 2002; Rao et al., 2002) .
A human caspase in the caspase-1 chromosomal cluster at 11q23 with significant homology to murine caspase-12 has been proposed to be the human orthologue of caspase-12. Interestingly, although mRNAs of this human caspase are expressed, the coding region has acquired apparent mutations in at least certain human populations (Fischer et al., 2002) . However, since there is no functional data confirming this conclusion, it remains highly hypothetical. Other possibilities, including acquisition of the caspase-12 function by another human caspase(s), and/or less a pronounced role of caspases in ER stress of human cells also remain a strong possibility.
Caspase-14
Caspase-14 appears to lack any clear designated role in cell death. It is present exclusively in simple and complex epithelia (Ahmad et al., 1998; Hu et al., 1998; Pistritto et al., 2002) , distinguishing it from the other, relatively ubiquitously expressed caspases. Several studies suggested that caspase-14 is transcriptionally induced during terminal differentiation of keratinocytes (Eckhart et al., 2000a, b; Lippens et al., 2000) , but another recent report suggested that high cell density and detachment from the extracellular matrix are the primary causes for the induction, rather than the differentiation per se (Pistritto et al., 2002) . In any case, all the studies agree that caspase-14 function does not appear to be related to apoptosis.
Caspase-8
The properties of caspase-8 are very well characterized and its role as an apical caspase in death receptor signaling has been well established through biochemical, molecular and cell biological studies. For example, caspase-8-deficient Jurkat cells are completely resistant to Fas and TRAIL-R2 and partially resistant to TNFainduced apoptosis (Juo et al., 1998; Bodmer et al., 2000; Sprick et al., 2000) . MEFs from the caspase-8À/À embryos were resistant to Fas, TNF and DR3 receptorinduced apoptosis, but remained sensitive to apoptosis through other pathways, such as UV irradiation and dexamethasone (Varfolomeev et al., 1998) . Interestingly, caspase-8 inactivation in Jurkat cells may not completely prevent death receptor-induced death, but rather shift the balance to nonapoptotic PCD pathways (Kawahara et al., 1998; Holler et al., 2000; Matsumura et al., 2000) .
Caspase-8À/À mice die at day 11.5 of the embryonic development, displaying impaired formation of cardiac muscles and prominent abdominal hemorrhage due to hyperemia (Varfolomeev et al., 1998) (Table 1 ). In addition, caspase-8À/À embryos possess decreased numbers of myeloid progenitor cells. FADDÀ/À mice displayed a similar phenotype, suggesting that death
Decade of caspases
A Degterev et al receptor signaling pathways play an important role in heart muscle development and hematopoiesis (Yeh et al., 1998) . FADD deficiency was also shown to block the activation of T cells and the development of B cells (Zhang et al., 1998; Kabra et al., 2001) , but similar studies have not been possible for caspase-8À/À mice due to their early embryonic lethality (Varfolomeev et al., 1998) . Interestingly, caspase-8 deficiency was recently discovered in a human kindred with an immunodeficiency syndrome . Individuals with homozygous caspase-8 mutations not only manifest defective lymphocyte apoptosis, characteristic of autoimmune lymphoproliferative disorder (ALPS) found in patients with defects in Fas signaling but also display additional defects in the activation of T, B and natural killer cells, which leads to immunodeficiency. While this finding remains to be confirmed by additional studies with conditional mouse mutants of caspase-8, the abovementioned data suggest a possible dual role of caspase-8 in both negative and positive regulation of immune response in vivo.
In addition to its role as an apical caspase, caspase-8 may be activated by downstream caspases, such as caspase-6, in a positive feedback loop (Cowling and Downward, 2002) , potentially resulting in Bid-dependent targeting of mitochondria. Several reports have also suggested that cytotoxic drugs can induce activation of the death receptor signaling mechanism through the Fas ligand (FasL)-independent induction of Fas clustering and caspase-8 activation (Micheau et al., 1999; Chen and Lai, 2001; Kulms et al., 2002) . Finally, caspase-8 was recently shown to substitute for caspase-3 function in caspase-3À/À mice following middle cerebral artery occlusion, a mouse model of stroke (Le et al., 2002) . All of these data suggest that caspase-8 possesses a wide variety of cell type-, cellular context-and signalspecific apoptotic functions in addition to the death receptor pathway.
Caspase-10
Caspase-10 is highly homologous to caspase-8 and is also recruited and activated by death receptors (Kischkel et al., 2001; Wang et al., 2001; Sprick et al., 2002) . Missense mutations in human caspase-10 have been found to be genetically associated with the autoimmune disease, ALPS type II, which is characterized by the abnormal homeostasis of lymphocytes and dendritic cells caused by defective FasL/Fas signaling . Since such mutant alleles of caspase-10 encode proteins with decreased enzymatic activity , caspase-10 must play an important role in death receptor signaling at least in some cell types in vivo, even though current in vitro data regarding its role are not conclusive (Kischkel et al., 2001; Wang et al., 2001; Sprick et al., 2002) . Caspase-10 may also function as a tumor suppressor, as several studies have reported finding missense mutations in caspase-10 in various tumors (Park et al., 2002; Shin et al., 2002a, b) .
Caspase-9
Caspase-9 is an important intracellular amplifier of caspase signaling downstream of mitochondria (Figure 3 ). Caspase-9 deficiency results in embryonicneonatal lethality with the onset of abnormalities at embryonic day 12.5 Kuida et al., 1998) (Table 1) . Interestingly, a few surviving homozygous mutants showed no obvious defects (Kuida et al., 1998) , which may be due to strain-specific genetic modifiers of the mutant phenotype (Leonard et al., 2002) . Caspase-9À/À embryos display an enlarged and malformed cerebellum due to a deficiency in apoptosis and caspase-3 activation. It remains to be determined, however, whether the cause of lethality in caspase-9À/À mice is truly a result of defective apoptosis or reflects an unknown, nonapoptotic function of this caspase.
Caspase-9À/À thymocytes, MEFs, embryonic stem (ES) cells and splenocytes showed defective apoptosis in response to a variety of stimuli (g and UV irradiation, cytotoxic drugs, dexamethasone, etc.), with the notable exception of death receptor pathways, which were not affected. Apaf-1À/À mice displayed a phenotype similar to that of caspase-9 , consistent with the model of caspase-9 and Apaf-1 being in the same pathway (Figure 3) . One notable exception is the retarded elimination of the interdigital webs in Apaf-1À/À mice (Chautan et al., 1999) , which is not seen in caspase-9À/À mice.
As noted above for the case of caspase-2, the interpretation of mouse caspase knockout data may be complicated by compensatory expression of different caspase family members. Also in this vein, the injection of anti-Fas antibody was lethal to both caspase-3À/À and caspase-9À/À mice, challenging the conclusion that Fas-induced hepatotoxicty involves the mitochondrial pathway (Yin et al., 1999) . However, the explanation for these results may lie in the compensatory induction of caspase-6 and -7 in caspase-3À/À and caspase-9À/À mice (Zheng et al., 2000) .
Disruption of Apaf-1/caspase-9 signaling by knockouts or other methods may also result in the activation of the alternative apoptotic apoptosome-independent mechanism. This principle was recently demonstrated for caspase-9À/À and Apaf-1À/À using the reconstitution of the hematopoietic compartment of the wild-type animals with transgenic fetal liver stem cells (Marsden et al., 2002) . In addition, nonapoptotic death mechanisms were reported to be activated in Apaf-1À/À ES cells (Haraguchi et al., 2000) and in caspase-3À/À and caspase-9À/À motor neurons (Oppenheim et al., 2001) .
Caspase-3, -6 and -7
These three highly homologous caspases form the execution subfamily. Analyses of apoptosis progression in MCF-7 cells, which lack caspase-3, showed that it is specifically required for the activation of the CAD/ DFF40-mediated internucleosomal DNA degradation (Tang and Kidd, 1998) . Caspase-3À/À mice in mixed 129X1/SvJ and C57BL/6J background were smaller Decade of caspases A Degterev et al than wild-type littermates, and most died prenatally, displaying neuronal hyperplasia due to the lack of apoptosis (Kuida et al., 1996) . In a pure C57BL/6J background, however, caspase-3À/À mice are viable with reduced fertility, suggesting the presence of a dominant strain-specific genetic suppressor (Leonard et al., 2002) .
Analysis of cell death in multiple cell types isolated from caspase-3 knockout animals revealed the complete inhibition of certain apoptotic hallmarks, such as membrane blebbing, DNA degradation and nuclear fragmentation Zheng et al., 1998) . On the other hand, caspase-3À/À MEFs were not protected from eventual death and displayed multiple apoptotic features, such as nuclear condensation and phosphatidylserine exposure. Similarly, depletion of caspase-3 in a cell-free apoptotic system inhibited most of the downstream events, including various substrate cleavages, DNA fragmentation, chromatin marginalization, etc., whereas elimination of either caspase-6 or -7 had no effect (Slee et al., 2001) . Thus, caspase-3 is important for the execution of certain, but not all, specific downstream events in apoptosis. In contrast to caspase-3, caspase-6 and -7 currently lack significant specialized functions.
The above-mentioned data create a paradox, since none of the executioner caspases seem to fully control execution of all the aspects of apoptosis. One possible explanation is that executioner caspases may have distinct roles in specific pathways, such as ER stress for caspase-7 (Rao et al., 2001) , but have redundant functions in the majority of the general apoptotic events and thus, abolition of all three may be required to observe complete inhibition of all apoptotic features. Alternatively, caspase-3 (Slee et al., 2001 ) may play a primary role, whereas abundant compensatory mechanisms create a novel network in case 'primary' caspase is missing, allowing most of the downstream events to occur. Multiple specific examples of such compensatory mechanisms have already been reported, for example, caspase-3 activity can be substituted for by caspase-8 (Le et al., 2002) ; inactivation of caspase-9 may lead to loss of caspase-3 and -6 activation, but not caspase-7 processing (Marsden et al., 2002) ; caspase-9 can replace caspase-2 (Troy et al., 2001) ; deletion of caspase-3 and -9 results in the compensatory activation of caspase-7 and -6 (Zheng et al., 2000) .
Molecular basis of caspase activation
Except for a number of special cases, caspase processing is mediated primarily by caspases themselves. This became obvious from the early observations that the simple overexpression of wild type, but not active site mutant caspase zymogens, in bacteria results in their spontaneous activation (Orth et al., 1996; Stennicke and Salvesen, 1997) . Similarly, cleavage between the large and small subunits with a concomitant increase in activity was observed in highly purified samples of caspase-1 (Thornberry et al., 1992; Ramage et al., 1995; Yamin et al., 1996) . A mechanistic explanation for autoactivation was provided by the observation that individual initiator caspases' processing sites often conform to their own substrate specificities (Figure 1d ) .
The ability to autoactivate implied the presence of residual activity in caspase zymogens, a possibility that was directly confirmed by active site affinity labeling of caspase-1 zymogen . However, caspase zymogens display greatly varying degrees of intrinsic activity (Figure 4a) . Initiator caspases such as caspase-8 and -9 are quite active as zymogens, whereas the executioner caspase-3 is much less active . In this sense, only executioner caspases are 'true' zymogens. The differences in zymogen caspase activity underscore the ability of the initiator caspases to serve as proximal responders to proapoptotic signals due to their high propensity towards autoactivation and necessitate the transactivation of the executioner caspases by activator ones (see below). The high intrinsic residual activity of initiator caspase zymogens also raises an intriguing question as to how such activity is suppressed in living cells.
One possible molecular explanation for the enhanced zymogenicity of the executioner caspases has been provided for caspase-3 (Roy et al., 2001) . Roy et al. described an Asp-Asp-Asp tripeptide inhibitory 'safety catch' present in the L2 loop of the caspase-3. This sequence, which is only found in caspase-3 and -7, forms an extensive network of salt bridges, stabilizing the inactive conformation and keeping zymogen activity under control. This mechanism is sensitive to low pH, which may account for the observed requirement for cytosolic acidification during apoptosome-mediated caspase-3 activation (Matsuyama et al., 2000) . In addition, direct interaction of the RGD peptide with the safety catch sequence may provide a mechanistic explanation as to why the RGD tripeptide can induce apoptosis of endothelial cells (Buckley et al., 1999; Roy et al., 2001 ).
Transactivation
As described in the preceding section, in many cases cells utilize intrinsically different mechanisms to activate initiator and executioner caspases (Figure 3 ). The former is achieved through interaction with the upstream signaling proteins, whereas the latter results from direct processing by activated initiator caspases. The mechanistic differences in the initiator and executioner caspase activation have been confirmed by structural analyses. It should be noted, however, that even though there are clear differences in the activation and behavior of the two caspase classes, they are not absolute and significant overlaps exist, as will be discussed below. The process of executioner caspase activation is termed 'transactivation' because it is mediated in trans by a heterologous caspase. The X-ray structures of active and zymogenic forms of caspase-7 have been reported, providing the opportunity to visualize directly the changes associated with the activation process (Shi, 2002) . Similar to the active caspases, procaspase-7 zymogen is a homodimer Pop et al., 2001; Riedl et al., 2001a) . The overall structure of the enzyme undergoes very minor changes upon activation, except for the catalytic loops L2, L3 and L4, which undergo dramatic conformational transitions (Figure 4b) . Three of the four loops (L2, L3 and L4) are away from each other in procaspase-7, in a conformation prohibitive to substrate binding, providing a molecular mechanism for its zymogenicity. The cleavage of Asp198 in the activation process frees the L2 0 loop from the neighboring small subunits in the caspase-7 homodimer and allows it to form a tight 'active bundle' with the L2 and L4 loops, which in turn produces the 901 rotation of L2, making the catalytic Cys accessible to solvent. This initial cleavage is the first, most important activation event. Subsequent processing steps (steps 2 and 3 in Figure 2c ) may or may not be needed for full activation depending on the caspase. Overall, the activation process triggers the necessary conformation change in caspase-7 to permit substrate binding (Figure 4b ). While this dynamic process of proteolytic activation is still to be confirmed with other caspases, the high degree of structural conservation in the caspase family suggests that this model is likely to be true for other caspases as well. The elegant activation mechanism described above, however, just primes caspase-7 for substrate binding. Comparison of the free active and inhibitor-bound caspase-7 structures, performed in the same study , provided a striking conclusion that the substrate-binding groove in free processed caspase-7 is still not properly formed because the L2 0 loop remains in the 'closed' conformation. The binding of substrate/ inhibitor triggers a 1801 flipping of the L2 0 loop, resulting in its upward movement towards L1-L4, completing the formation of the 'active bundle'. This observation has led to the proposal that the binding of the substrate by caspases is a dynamic 'induced-fit' process (Shi, 2002) . Therefore, caspase processing and substrate binding represent a continuous sequence of conformational changes leading to the 'loop bundle' formation and molecular ordering of the active center.
Two additional interesting questions were answered by caspase-7 structural studies. First, it has long been proposed that caspase heterodimers may form through an interdigitation mechanism, which postulates that the small and large subunits forming the structural unit in the heterodimer come from different caspase monomers . However, the zymogen structure showed that each unit is composed of the subunits originating from the same polypeptide chain. Second, the concept of the loop bundle, formed by the sequences contributed by different subunits of the same monomer (L4 and L2) and the neighboring polypeptide as well (L2 0 ) underscores the critical importance of dimerization for enzyme activity.
The proposed mechanism for executioner caspase activation clearly postulates that the removal of the Nterminal propeptide is neither required nor beneficial for activation. This aspect of the model has been confirmed experimentally for multiple caspases, including caspase-3 Pop et al., 2001) . However, a recent study suggested that propeptide cleavage is critical for caspase-6 activation, which may suggest that additional, as yet unknown structural determinants, are involved in the activation process (Cowling and Downward, 2002) .
Allosteric regulation
Caspase-9 is unique among all the caspases as proteolytic cleavage is neither sufficient nor necessary for its activation (Rodriguez and Lazebnik, 1999; Renatus et al., 2001) . In living cells, caspase-9 is present in the cytosol predominantly in the monomeric form with a small population of dimers (Renatus et al., 2001) . The active site of the monomer is in the inactive conformation and its activation is driven by a dimerization-dependent conformational change, which was characterized through X-ray structural studies (Renatus et al., 2001) . It is not clear whether a small amount of caspase-9 dimer is actually present in living cells or formed as a result of the isolation process. According to the model of caspase-9 activation, the interaction surface of the neighboring monomer provides an acceptor site for the activation loop (Figure 4c) , and this binding results in the rearrangement in the substrate-binding pocket and reorientation of the catalytic Cys to form a functional active site (Figure 4c) (Renatus et al., 2001) . Interestingly, structural studies showed that the caspase-9 dimer possesses only one active site, but the significance of this finding is currently unknown (Renatus et al., 2001) .
The apoptosome complex, consisting of Apaf-1, cytochrome c and caspase-9, is proposed to serve as an allosteric regulator of caspase-9, promoting its homodimerization and activation (Renatus et al., 2001; Shiozaki et al., 2002) . Thus, the apoptosome complex can be considered as a holoenzyme, in which caspase-9 is 1000-fold more active than its monomeric form (Rodriguez and Lazebnik, 1999) .
The allosteric mechanism may also be utilized by other caspases. For example, it may contribute to the activation of caspase-1 and -5 in the 'inflammasome' complex involving the Apaf-1-like adaptor NALP1 (Martinon et al., 2002) .
Induced proximity mechanism
Caspase-8 processing may represent yet another mechanism of caspase activation with features of both proteolytic and allosteric regulation. The caspase-8 zymogen possesses significant activity, but proteolytic cleavage is still clearly required for its full activation (Muzio et al., 1998) . Since caspase-8 is the most upstream caspase in the death receptor signaling pathway and its activation is brought about as a result of the adaptor-mediated multimerization, an 'induced proximity' mechanism for its processing has been suggested (Muzio et al., 1998) . In this model, the increased local concentration of the caspase-8 zymogen induced by FADD-mediated trimerization results in the intermolecular processing of caspase-8. Consistent with this model, FK1012-induced dimerization of caspase-8 fused to the FKBP12 protein indeed resulted in enzyme activation (Muzio et al., 1998) .
The induced proximity model may need to be updated based on the recent studies of FLIP L -mediated caspase-8 activation (Chang et al., 2002; Micheau et al., 2002) . FLIP is a catalytically inactive, close homologue of caspase-8 and plays an important role in the regulation of caspase-8 activation and inhibition of cell death in vivo (Yeh et al., 2000) . Two splice variants of FLIPs have been described: short and long (Irmler et al., 1997) . The former is the homologue of the caspase-8 prodomain only, whereas the long form also contains a pseudocatalytic domain lacking the active site Cys. FLIP s can directly block caspase-8 recruitment into the DISC (Kirchhoff et al., 2000) . In contrast, FLIP L cannot prevent the recruitment of caspase-8 into the DISC, and its presence in the DISC even stimulates the first cleavage step of caspase-8 zymogen, but blocks further processing (Krueger et al., 2001) , resulting in local activation of caspase-8 within the DISC complex (Chang et al., 2002; Micheau et al., 2002) . Based on the results of the molecular modeling of caspase-8/ FLIP L complex, it has been proposed that FLIP L can induce a reordering of the caspase-8 catalytic center in a manner similar to the dimerization-driven caspase-9 activation (Micheau et al., 2002) . The L2 loop of caspase-8 may be long and flexible enough to be subsequently autocleaved, resulting in the generation of the partially processed, but fully active heterodimer of FLIP L and p43/41 (prodomain plus large subunit) and p12 subunits of caspase-8. Thus, caspase-8 activation may include features of both allosteric and processing-based mechanisms. In contrast to that of caspase-8, the L2 loop of caspase-9 may be extended enough to eliminate the need for proteolytic activation completely (Renatus et al., 2001) .
A complex network of caspase cross-activation As described above, the initiator-executioner dichotomy of the caspase family fits well with their established activation mechanisms. However, multiple studies clearly demonstrate that this subdivision primarily applies to the initial stages of the apoptotic signaling, with the complex network of caspase cross-activation occurring in the downstream steps of apoptosis.
Recombinant caspase-1, -2, -3, -6, -7 and -8 can process various in vitro translated caspase zymogens (Van de Craen et al., 1999) . For example, caspase pairs 8/3, 6/7 and 6/3 were found to form reciprocal feedback loops. Caspase-8 was shown to process all caspases efficiently. Caspase-1 and -11 were found to be able to activate executioner caspases, but not vice versa. Caspase-2 was shown to be activated by a host of caspases, but it failed to process any tested caspases. Overall, these findings underscore the complexity of the caspase transactivation patterns, with executioner caspases capable of processing the normally upstream activator molecules in vitro.
An intricate network of caspase transactivation has also been demonstrated in a cell-free apoptosis system (Slee et al., 1999) . The addition of cytochrome c to postnuclear Jurkat (JK) cell lysates resulted in the initiation of the caspase-9/caspase-3 axis, with caspase-3 subsequently processing caspase-2 and -6 and the latter activating apical caspase-8 and -10. In addition to caspase-3, caspase-9 also processed caspase-7, while caspase-3 formed a feedback loop to cleave caspase-9. The primary function of the latter event is to remove the binding site for XIAP (X-linked inhibitor of apoptosis) from the L2 0 loop of the caspase-9, making it refractive to inhibition .
The above observations made in vitro provide just a brief insight into the potential complexity of the putative downstream caspase cross-activation networks induced inside cells. Although upstream activation may initially involve particular caspases, it is likely that a vast array of additional family members is eventually activated as well. Such transactivation may blur the distinctions between the 'initiator' and 'executioner' caspases and may serve (a) to expand the repertoire of accessible caspase substrates, (b) to stimulate diverse downstream signaling processes (e.g. cytokine processing versus
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Additional regulatory mechanisms for caspases
Most caspases are constitutively expressed in multiple cell types. The activation mechanisms described above represent by far the most important ways to regulate caspase activity. However, additional regulatory mechanisms have also been uncovered in recent years.
Gene expression
The requirement for new protein synthesis in certain apoptotic paradigms provided the first hint of an endogenous suicide mechanism (Lockshin, 1969) . Even though subsequent studies suggested that apoptosis, in most cases, does not require new protein synthesis, regulation of caspase transcription does play a role in certain circumstances. A dramatic demonstration of this notion came from the analysis of murine caspase-11. The level of this caspase in healthy resting cells is very low, but treatment with LPS or other pathological stimuli such as ischemia in vivo leads to a dramatic transcriptional upregulation of caspase-11 expression Kang et al., 2000) . The putative human caspase-11 homologue, caspase-5, is also transcriptionally upregulated by LPS (Lin et al., 2000) , but it remains to be determined if levels of the protein also increase. Caspase-14 is another example of transcriptionally regulated caspase (see above) (Eckhart et al., 2000a) . A role of the oncogenic E2F transcription factor in regulating caspase expression was recently proposed by Nahle et al. (2002) . It was found that E2F deregulation (caused by E2A oncogene overexpression or loss of the tumor suppressor Rb) resulted in the accumulation of zymogenic forms of multiple caspases, which appears to potentiate p53-mediated apoptotic signals. These results may explain the increased sensitivity of oncogeneexpressing cells to multiple apoptotic stimuli, which is in many cases exploited by cancer therapy.
Nitrosylation and oxidation
The catalytic cysteine of caspases is very active and susceptible to modifications. It has been demonstrated that nitric oxide (NO) donors can directly inhibit caspase activity through active site nitrosylation Mohr et al., 1997) and this mechanism was implicated in the NO-mediated inhibition of apoptosis or inflammatory cytokine production. On the other hand, multiple reports also suggested that NO can cause nitrosative stress, DNA and mitochondrial damage and, as a result, induce apoptosis and caspase activation (see for a review, see Kim et al., 2002) . Therefore, the outcome of NO generation may depend on the level of its production and cellular context.
Similarly, excessive generation of reactive oxygen species (ROS) may lead to the inhibition of caspases, even though ROS possesses high intrinsic toxicity. In many cases, inhibition of caspases by such stimuli may not result in the alleviation of death, but rather in a switch from apoptosis to necrosis, which is defined as a nonspecific, caspase-independent death caused by the overwhelming stress (Nicotera et al., 1999) .
Phosphorylation
Phosphorylation is the most widely used cellular regulatory mechanism, but the only available example of phosphorylation directly regulating caspase activity is the inactivation of human caspase-9 by Akt (Cardone et al., 1998) . Interestingly, this mechanism may have been developed late in evolution, since murine caspase-9 apparently lacks the cognate phosphorylation site present in human caspase-9 (Fujita et al., 1999) . Phosphorylation, however, has been shown to play an important role in the regulation of the other steps in apoptosis signaling (see other reviews in this issue of Oncogene). One possible explanation for the lack of direct phosphorylation-dependent caspase modulation is that phosphorylation is best suited for the rapid and reversible modulation of signaling networks and therefore may not be appropriate for regulating caspases, whose activation often initiates an irreversible process.
Ubiquitination and degradation
Increasing attention has been paid in recent years to the ubiquitination of caspases by IAPs (see review of IAP family in this issue of Oncogene).
Caspase inhibitors
Caspases are the only proteases that are not compartmentalized in living cells. Their potent proapoptotic activity mandates that they must be kept under tight control in order for healthy cells to survive. In this section, we discuss viral caspase inhibitors that target the cellular apoptosis machinery that is activated upon viral infection, as well as the synthetic inhibitors that have been widely used to examine the roles of caspases in regulating cellular processes.
p35
Apoptosis is the most potent host defense mechanism to eliminate virally infected cells. It is not surprising, therefore, that many viruses have developed countermeasures to suppress apoptosis. The baculoviral p35 protein was first discovered through its ability to inhibit apoptosis in virally infected insect cells (Clem et al., 1991) and later shown to inhibit multiple active caspases directly by acting as a pseudosubstrate (Bump et al., 1995; Xue and Horvitz, 1995) . p35 is first cleaved by caspases, recognizing the DQMD sequence in the reactive site loop (RSL) of p35, followed by the formation of the covalent adduct between the P1 Asp87 residue of p35 and active site Cys of caspases (Bump et al., 1995) .
The molecular mechanism of p35 activity was established through X-ray crystallographic analysis of the p35/caspase-8 complex (Xu et al., 2001) . The initial cleavage by caspases results in significant conformational changes in p35, including the formation of an internal b sheet (Xu et al., 2001) , surface exposure of the Cys2 residue of p35, normally buried in the hydrophobic core (Fisher et al., 1999) and protein stabilization (Riedl et al., 2001b) . The released Cys2 residue inserts into the caspase-8 active site and likely forms a hydrogen bond with the catalytic His residue. This interaction completely blocks the solvent accessibility of the His residue and also induces its rotation into a position unfavorable for catalysis, disrupting the catalytic triad and resulting in the stabilization of the covalent adduct formed with the catalytic Cys287 (Xu et al., 2001) . Consistent with this mechanism, Cys2 mutations convert p35 into an efficient caspase substrate, abrogating covalent adduct formation (Riedl et al., 2001b; Xu et al., 2001 ). In the case of executioner caspases, p35 also appears to interact with the surface loop 381, which is missing in initiator caspases, explaining the preference of p35 for the executioner subgroup (Eddins et al., 2002) .
CrmA
CrmA (a cytokine response modifier gene) protein of cowpox virus was the first identified inhibitor of caspases (Ray et al., 1992) . CrmA displays a preference for caspase-1 and -8 in vitro (Table 2) . Consistent with this observation, CrmA prevented the processing of IL1b by caspase-1 and inhibited TNFa-and Fas-mediated apoptosis (Enari et al., 1995; Los et al., 1995; Miura et al., 1995) . On the other hand, despite a high secondorder rate constant and a low nanomolar K i against caspase-9 in vitro, caspase-9 most likely is not a physiological target of CrmA, based on the inability of CrmA to block caspase-9-mediated mitochondria-dependent cell death pathways (Datta et al., 1997a; Orth and Dixit, 1997) .
Structurally, CrmA belongs to the serpin class of inhibitors, but unlike other members of this class, which target serine proteases, CrmA inhibits cysteine proteases. What makes this inhibitor truly unique is its ability to also inhibit the serine protease granzyme B, which shows similar substrate specificity to caspases (Quan et al., 1995) , making CrmA a dual Ser/Cys protease inhibitor.
p35 and CrmA are both pseudosubstrate inhibitors and their interaction with caspases involves caspase substrate recognition subsites S1-S4 and corresponding P1-P4 inhibitor residues (Ekert et al., 1999b; Xu et al., 2001) , with additional extended interaction surfaces surrounding S1-S4/P1-P4 sites proposed to further increase the affinity of binding (Xu et al., 2001) . The caspase recognition motifs present in the RSL loops of p35 and CrmA are DQMD and LVAD, respectively, and were shown to play a significant role in their specificity towards particular caspase family members (Ekert et al., 1999b) . However, additional parameters, such as the geometry of the active centers of individual caspases, may also contribute to their relative affinities for CrmA and p35 . 
IAPs
Inhibitor of apoptosis protein (IAP) was also originally identified in baculovirus (Crook et al., 1993) . Homologues of IAP proteins have subsequently been discovered in all eucaryotes from yeast to humans, making them very important physiological regulators of cell death (see review in this issue of Oncogene).
Peptide-based caspase inhibitors
The development of peptide-based caspase inhibitors (Thornberry et al., 1992) provided valuable tools for studies of caspase family members and apoptosis in general. The design of these inhibitors is based on the tetrapeptide caspase recognition motif and therefore the selectivity of the inhibitors parallels the caspase substrate specificities described in the previous sections ( Figure 1c , Table 2 ) (Garcia-Calvo et al., 1998). However, there are also differences in the mechanism of action of p35 and CrmA. For example, whereas caspase cleavage is an integral part of inhibition by p35 (see above), in case of CrmA, caspase cleavage has been shown to be inactivating (Komiyama et al., 1994) . The introduction of an aldehyde group at the C-terminus of the tetrapeptide results in the generation of reversible inhibitors (Graybill et al., 1994) , whereas chloromethyl ketone (Estrov et al., 1995) , diazomethyl ketone (Thornberry et al., 1992) and acyloxymethyl ketone Thornberry et al., 1994) at this position create inhibitors that irreversibly inactivate the enzymes. The latter group comprises the most selective and potent caspase inhibitors, with the second-order rate constants reaching 2 Â 10 6 /M/s (Dolle et al., 1995) . However, all these inhibitors possess several disadvantages, such as toxicity of the leaving group, low half-life in cells, poor cell permeability, modest selectivity towards individual caspases (or even caspases versus other proteases) and a lack of oral bioavailability, which limits their use to mostly cell-based studies. Since these synthetic peptide inhibitors are relatively poor in their ability to discriminate among different caspase family members, these reagents are best suited to demonstrate the involvement of caspases and apoptosis in general in a particular process, rather than pinpointing a role for a specific caspase. For further detailed reviews, see Livingston, (1997) , Ekert et al. (1999a) , Rudel (1999) , Talanian et al. (2000) .
Nonpeptide caspase inhibitors
Small molecule nonpeptide inhibitors of caspases are currently in development and may overcome some of the limitations of the peptide-based inhibitors. The efficacy of nonpeptide inhibitors has been demonstrated in various animal models of pathology. Such inhibitors were shown to block apoptosis in neutrophils, chondrocytes and primary dopaminergic neurons efficiently in vitro (Lee et al., 2000; Bilsland et al., 2002) as well as in vivo in animal models of septic shock (Grobmyer et al., 1999; Hotchkiss et al., 2000) , liver injury (Natori et al., 1999; Deaciuc et al., 2001; Hoglen et al., 2001 ) and neonatal hypoxic-ischemic brain injury . This new and rapidly developing area may lead to the clinical utilization of the extensive information generated in the caspase field over the past 10 years.
Caspase targets
It is important to establish several basic concepts when examining the role of caspases in the execution of cell death. Firstly, caspases do not degrade other proteins. Due to their strict substrate recognition specificity, caspases cleave targets at one or a few highly selective sites. Secondly, even though caspases do cleave some structural proteins required for the maintenance of cell structure, they also frequently target signaling proteins, such as kinases. The cleavage of such signaling molecules results in the activation or suppression of specific downstream pathways, which in turn execute cell death. Therefore, caspases serve as signaling mediators that orchestrate a complex web of downstream execution pathways. In that sense, caspases can act in a manner analogous to kinases, with the notable exception that protein modifications introduced by caspases are irreversible, underscoring the terminal nature of apoptosis.
Consistent with the substrate specificity considerations presented above, caspases most likely cleave only a very small subset of cellular proteins. Close to 100 substrates have been identified thus far (see reviews for detailed listings Earnshaw et al., 1999; Li and Yuan, 1999; Utz and Anderson, 2000) . Here, we provide only a brief overview of the current state of the field. Based on the analyses of their cellular function, the caspase targets can be subdivided into six major categories: (1) proteins directly involved in the regulation of apoptosis, (2) proteins mediating/regulating apoptotic signal transduction (e.g. protein kinases), (3) structural and essentialfunction proteins, (4) proteins required for cellular repair, (5) proteins regulating the cell cycle and (6) proteins involved in human pathologies ( Figure 5 ).
It should be noted that in many cases, there is very limited information regarding the cleavage of specific substrates, making it difficult to determine whether it represents a universally important event in apoptosis or is restricted to a particular cell type or stimulus. This consideration is especially relevant for substrate classes 2, 5 and 6, whereas proteolysis of many apoptotic, structural and repair proteins, such as caspases, ICAD/ DFF45, keratins, lamins and poly(ADP-ribose) polymerase, is considered general characteristic feature of apoptotic cell death. In addition, very frequently the role of putative caspase substrates in regulation/execution of apoptosis is investigated via the overexpression of mutated, caspase-uncleavable versions, which may not accurately represent the endogenous functions of these proteins. Therefore, at least some conclusions regarding the involvement of specific caspase substrates in downstream apoptotic events remain to be confirmed in the future.
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Apoptotic proteins
Caspases are the most obvious examples of apoptotic factors targeted by caspases (see above). In addition, multiple additional upstream and downstream mediators of apoptosis are also cleaved by caspases. They can be further subdivided into pro-and antiapoptotic categories based on their functions.
In the proapoptotic category, the Bcl-2 family member Bid is cleaved by caspase-8 following death receptor signaling, which results in its activation and mitochondrial translocation Luo et al., 1998) . Recently, caspase-2 was also shown to cleave Bid (Guo et al., 2002) . Another prominent target of caspases is DNA fragmentation factor 45 kDa subunit (DFF45/ ICAD) Enari et al., 1998) . Caspase cleavage removes the N-terminal CIDE-N interaction domain, abrogating DFF45/ICAD-mediated suppression of the catalytic DFF40/CAD subunit (Inohara et al., 1999; Lugovskoy et al., 1999) , which plays a critical role in the internucleosomal DNA degradation characteristic of apoptosis (Sakahira et al., 1999) .
In addition to proapoptotic factors, caspases also cleave and, in most cases, inactivate antiapoptotic proteins. For example, the antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-xL, are cleaved between their N-terminal BH4 and BH3 domains following Sinbis virus infection or IL-3 deprivation, resulting in the conversion of these proteins into the proapoptotic factors (Cheng et al., 1997; Clem et al., 1998) . However, it is not currently clear whether this cleavage represents a ubiquitous positive feedback mechanism or a cell type or stimulus-specific event. Caspase inhibitors, such as IAPs (see review in this issue of Oncogene) and FLIP L (Scaffidi et al., 1999) , are also cleaved by caspases, but the functional significance of these observations is currently unclear.
Finally, although proapoptotic Bcl-2 family members may induce cytochrome c release upstream of (and, therefore, independent of) caspase activity (Kluck et al., 1997; Yang et al., 1997) , additional mitochondrial damage, as detected by the loss of inner membrane potential, is often caspase-dependent. However, the specific targets in this case are unknown (Bossy-Wetzel et al., 1998; Li et al., 1998) .
Protein kinases
A large number of protein kinases are cleaved by caspases. Some are involved in the inhibition of apoptosis, while others may potentiate apoptosis or mediate specific downstream execution events.
The most notable antiapoptotic kinase target of caspases is Akt, which is cleaved following matrix detachment in epithelial cells (Bachelder et al., 1999 (Bachelder et al., , 2001 ). Akt mediates cell survival through multiple pathways, including the phosphorylation of proapoptotic Bcl-2 family member Bad (Datta et al., 1997c; del Peso et al., 1997) and transcription factor Forkhead (Brunet et al., 1999) . RIP kinase, the cell survival signaling component of the DISC complex, is also cleaved by caspase-8, causing its inactivation and the suppression of antiapoptotic RIP-mediated NF-kB induction Martinon et al., 2000) . FAK kinase transduces cell survival signals from the extracellular matrix through a Raf-1 pathway involving MAP kinases Erk-1 and Erk-2 and phosphatidylinositol 3-kinase, which is an activator of Akt (see for a review Schlaepfer et al., 1999) . FAK is cleaved and inactivated during apoptosis induced by multiple stimuli (e.g. c-myc overexpression, death receptor signaling, staurosporine and camptothecin), which contributes both to the loss of survival signals and matrix detachment (Crouch et al., 1996; Wen et al., 1997; Gervais et al., 1998) . Multiple additional components of this pathway, such as Raf-1, Akt, Cbl and Cbl-b, were also reported to be inactivated by caspase cleavage following Fas engagement (Widmann et al., 1998b) .
The activation of transcription factor NF-kB is an important prosurvival mechanism (for reviews see de Foo and Nolan, 1999) . The p65/ RelA subunit of NF-kB (Levkau et al., 1999) and upstream activating kinase IKKb (Tang et al., 2001) may be inhibited through caspase-dependent cleavage, providing a way of tipping the balance towards cell death.
A number of proapoptotic kinases were reported to be cleaved and activated by caspases. Fas signaling results in caspase-3-mediated cleavage of PAK2 (p21-activated kinase 2), separating the N-terminal regulatory Figure 5 Caspase substrates. The list of the most relevant caspase substrates (see text for further details). Specific information regarding the role of each substrate and precise processing site can be found elsewhere (Earnshaw et al., 1999; Utz and Anderson, 2000) Decade of caspases A Degterev et al and C-terminal catalytic domains and generating the constitutively active form of PAK2, which contributes to the formation of apoptotic bodies (Rudel and Bokoch, 1997) . MEKK1 is another kinase activated during genotoxic stress and Fas-induced apoptosis (Deak et al., 1998; Widmann et al., 1998a) . Apoptotic MEKK1 signaling involves JNK activation (Deak et al., 1998) . Mst1 kinase is both phosphorylated and cleaved during apoptosis induced by Fas and staurosporine (Graves et al., 1998; Lee et al., 1998) . The activation of this kinase also enhances apoptosis through the activation of JNK (Watabe et al., 1999) and/or the nuclear translocation of the cleaved kinase, specifically contributing to chromatin condensation (Ura et al., 2001 ). Mst1-related, Mst2, SLK and SPAK kinases, are also cleaved and activated in response to multiple stimuli (Graves et al., 1998; Lee et al., 1998; Johnston et al., 2000; Sabourin et al., 2000) . ROCK1 kinase was recently reported to be cleaved and activated in response to TNFa and this event was shown to be both necessary and sufficient for apoptotic membrane blebbing (Coleman et al., 2001) . Finally, a number of protein kinase C isoforms and related proteins are also proteolytically activated during apoptosis (Emoto et al., 1995; Ghayur et al., 1996; Cryns et al., 1997; Datta et al., 1997b; Shao et al., 1997; Endo et al., 2000) . Overall, these results paint a picture of a complex network of downstream kinase pathways controlling various aspects of apoptosis execution activated or inactivated by caspases, reinforcing the critical role played by caspases in apoptotic signaling.
Structural and essential function proteins
In the demolition phase of apoptosis, caspases make a few strategic cuts in a number of critical locations in order to dismantle the cellular architecture, a process that is critical for the completion of apoptosis. For example, cleavage of gelsolin leads to its activation and, subsequently, gelsolin-mediated disruption of the actin filament network, which may specifically contribute to cells rounding up and detaching from the matrix during apoptosis (Kothakota et al., 1997) . A number of intermediate filament proteins (keratins 18 and 19, vimentin) are also cleaved by caspases (Caulin et al., 1997; Ku et al., 1997; Prasad et al., 1998) . Interestingly, keratin 18 cleavage has been recently used to demonstrate a role of scaffolding protein DEDD in directing activated caspase-3 towards specific substrates , which may represent yet another mechanism regulating caspase function. Caspase cleavage of the adherent junction proteins b-catenin and plakoglobin/g-catenin leads to the disruption of cell-cell interactions, which may in turn attenuate their prosurvival signaling (Brancolini et al., 1998; Schmeiser et al., 1998) .
Nuclear fragmentation critically depends on the disruption of the nuclear filamentous network through the cleavage of lamins A, B1 and C by caspases Rao et al., 1996) . Lamin cleavage by caspase-6 appears to be one of the very few reported examples of the requirement for a nonredundant activity of a specific executioner caspase (Ruchaud et al., 2002) . The proteolytic disruption of multiple additional nuclear proteins, such as mitotic apparatus proteins NuMA, topoisomerases I and II, RNA polymerase I and upstream binding factor (UBF), may also contribute to nuclear collapse (Casiano et al., 1996; Greidinger et al., 1996) .
Finally, the basic mRNA splicing machinery is also affected during apoptosis through processing of several splicing factors by caspases. These include the 70 kDa U1-specific factor (Casciola-Rosen et al., 1994) and the heteronuclear riboproteins C1 and C2 (Waterhouse et al., 1996) .
Proteins required for cellular repair
Failure to repair or restore cellular functions in response to cellular distress is one of the main triggers of apoptosis and therefore induction of apoptosis in many cases may follow activation of the cellular repair networks. Both apoptosis and cellular maintenance/ repair pathways are resource-demanding processes and may compete for valuable cellular assets, such as ATP. In addition, apoptotic execution itself causes cellular damage, which may trigger further activation of the repair pathways and create a feedback loop unfavorable for apoptosis. Finally, cellular maintenance pathways may also interfere with apoptosis through activation of downstream events that are not compatible with apoptosis. For instance, repair responses typically trigger cell cycle arrest, whereas apoptosis is associated with the upregulation and/or activation of many cell cycle related proteins (see below).
The shutdown of cellular repair may accelerate the execution of apoptosis. DNA-dependent protein kinase (DNA-PK), which plays a critical role in the induction of DNA repair in response to double-strand breaks (Lees-Miller, 1996) , is one of the upstream caspase targets during apoptosis (Casciola-Rosen et al., 1995; Song et al., 1996) . Human Rad51 and ATM proteins, involved in recombination DNA repair, are also cleaved (Flygare et al., 1998; Hotti et al., 2000; Tong et al., 2000) . Interestingly, the same DNA repair proteins that are inactivated by caspases also appear to mediate the induction of apoptosis. For example, DNA-PK cooperates with p53 in the induction of cell death in response to DNA damage . These observations suggest that many DNA repair enzymes possess multiple functions including repair, cell cycle arrest and induction of apoptosis, and the extent of cellular damage may determine which function takes over (Bernstein et al., 2002) .
The significance of cellular energy balance for apoptosis execution is best illustrated by the studies of another DNA repair enzyme: poly(ADP-ribose) polymerase (PARP). PARP is activated by single-and double-strand DNA breaks and catalyses the attachment of ADP-ribose polymers to multiple nuclear factors, facilitating repair (for a review see Smulson et al., 2000) . When activated, this process consumes large amounts of NAD þ , thereby indirectly depleting the cellular ATP store. Since the loss of cellular ATP was demonstrated to abrogate apoptosis, resulting in the induction of necrosis (Leist et al., 1997; Nicotera et al., 1998) , this may explain the observed caspase-mediated cleavage and inactivation of PARP during apoptosis (Kaufmann et al., 1993) .
Cell cycle proteins
A number of cell cycle inhibitory factors are cleaved during apoptosis. Those include Cdc27, a component of the ubiquitin ligase complex degrading mitotic cyclins, Wee1, a kinase providing inhibitory phosphorylation of Cdks, and two Cdk inhibitors, p21 CIP1 and p27 KIP1 (Levkau et al., 1998; Zhou et al., 1998) . These degradation events result in the accumulation of active Cdc2 and Cdk2, but surprisingly, do not result in mitotic entry (Zhou et al., 1998) . In addition, death receptor signaling was found to cause caspase-dependent inactivation of another proliferation inhibitor, Rb (An and Dou, 1996; Janicke et al., 1996) . Overall, induction of apoptosis appears to coincide with the activation of multiple cell cycle-associated factors through cleavage and inactivation of their inhibitors. Cleavage of cell cycle regulators may promote apoptosis signaling by multiple means as illustrated by recent studies. In one example, Cdc2 was shown to phosphorylate the proapoptotic Bcl-2 family member Bad at a site, which inhibits its interaction with Akt and thereby activates its proapoptotic activity (Konishi et al., 2002) . In another example, loss of Rb was found to promote accumulation of procaspases (Nahle et al., 2002) . The cleavage of cell cycle regulators may have evolved as a specific tumor suppressor mechanism aimed at ensuring induction of cell death in response to improper cell cycle signaling by oncogenes.
Disease-related proteins
Since the improper regulation of apoptosis contributes to a variety of diseases, caspases represent promising therapeutic targets (Nicholson, 2000; Talanian et al., 2000) . In addition to their role in apoptosis, caspases may also be involved in the direct cleavage of diseaseassociated factors. Two of the most striking examples are pertinent to neurodegenerative disorders: Huntington's disease (HD) and Azheimer's disease (AD).
HD is caused by the genetic amplification of CAG repeats, which encode polyglutamine (polyQ), in the Nterminus of the huntingtin protein . Caspases, including caspase-2 and -3, may contribute to the generation of expanded polyQ fragment of huntingtin through cleavage in the cluster of DXXD sites (Goldberg et al., 1996; Wellington et al., 2002) . Processed expanded polyQ forms intranuclear aggregates that are proposed to play a key role in the progressive neuronal dysfunction and neuronal loss characteristic of HD by recruiting and activating caspase-8 and -10 as well as other proteins (Sanchez et al., 1999; U et al., 2001) .
HD is just one of the eight polyglutamine expansioninduced neurodegenerative disorders . Other disease loci-encoded factors, atropin-1 (DRPLA disease), ataxin-3 (SCA-3) and androgen receptor (Kennedy's disease), have also been found to be caspase targets and mutations of the putative caspase target sites in atropin-1 and androgen receptor were shown to diminish their cytotoxicity (Ellerby et al., 1999a, b) .
The oligomerization of Ab 1-42 and Ab 1-40 peptides, which arise from the b and g-secretase cleavage of the transmembrane portion of the amyloid precursor protein (APP), is critical to the progressive dysfunction and loss of cholinergic neurons in AD (Selkoe, 2000 (Selkoe, , 2001 . Caspase-3 has been found to cleave the cytosolic tail of APP at the residue 720, which is C-terminal to the g-secretase site, stimulating the subsequent g-secretase cleavage step approximately fivefold (Gervais et al., 1999) . The released cytosolic portion of APP has also been suggested to play a separate role in the disease pathophysiology (Nishimura et al., 2002) . In addition, oligomeric Ab was shown to mediate caspase-dependent apoptosis in isolated neuronal cultures (LaFerla et al., 1995; Troy et al., 2000) . However, the role of caspases in APP processing and neuronal degeneration caused by Ab peptide remains to be verified in vivo.
Nonapoptotic functions of caspases
In addition to their roles in apoptosis, multiple caspases possess additional functions not related to the cell death, which may or may not involve other components of the cell death machinery.
Selected examples of such functions have already been described in preceding sections. For example, caspase-1 and -11 play a role in the regulation of inflammatory response. The components of the apoptotic death receptor pathway have been found to both downregulate the immune response, by promoting apoptosis, as well as to stimulate the immune response, by promoting lymphocyte proliferation and activation, as evidenced by the requirement for FADD and caspase-8 in lymphocyte activation (Kabra et al., 2001; Chun et al., 2002) .
Caspases may also be involved in terminal differentiation. A recent study showed that caspase-3-mediated activation of MST1 kinase is critical for proper muscle differentiation, and this process is defective in caspase-3À/À mice (Fernando et al., 2002) . Since MST1 activation is also a part of the apoptotic response, it is unclear how these two pathways are separated. In addition, myeloid, monocyte and erythrocyte differentiation may also require caspase activity (Pandey et al., 2000; Zermati et al., 2001; Sordet et al., 2002) . Keratinocyte differentiation may involve caspase-14 (see above). Overall, these results indicate that caspases are involved in a variety of processes other than apoptosis and this list will likely grow in the coming years.
Caspases in pathophysiology of disease
Apoptosis is a major mechanism aimed at insuring proper development and organism homeostasis. Due to its role in the elimination of virally infected and damaged cells, apoptosis also plays a central role in the prevention of diseases. The enormous power of this process, however, makes the dysregulation of apoptosis deleterious for the organism and can lead to a host of pathologies (Thompson, 1995) . Abnormal activation of apoptosis is implicated in tissue degeneration during ischemia, AIDS, neurodegeneration and septic shock. The induction of apoptosis in these diseases may significantly contribute to their pathogenesis.
Caspase activation has been demonstrated in many diseases characterized by abnormal cell death. For example, cleaved caspases have been detected in AD LeBlanc et al., 1999; Stadelmann et al., 1999) , ALS (Pasinelli et al., 1998 ), Parkinson's disease (Hartmann et al., 2000; Tatton, 2000) , HD (Sanchez et al., 1999) and ischemic brain (Namura et al., 1998; Matsushita et al., 2000) . Inappropriate caspasemediated fodrin cleavage has been implicated in the pathophysiology of Sjogren's syndrome, an autoimmune disorder associated with excessive tissue destruction (Hayashi et al., 2000; Inoue et al., 2001) . Similarly, caspase activation was shown to correlate with spinal/ head trauma (Clark et al., 1999; Springer et al., 1999) and epilepsy (Henshall et al., 2000) . Finally, the caspase-1 subfamily of caspases specifically contributes to inflammatory disorders associated with defects in cytokine processing, such as rheumatoid arthritis (RA) and inflammatory bowel disease (Crohn's disease) (Randle et al., 2001; Siegmund, 2002) .
The lack of proper caspase activity can also lead to pathologies. For example, the inactivation of caspase-10 may give rise to ALPS II (see above). Mutations of caspase-8 and -10 have been found in multiple human tumors (see above and Liu et al., 2002; Shin et al., 2002b) . In addition, IAPs and FLIP are frequently overexpressed in cancers and may contribute to tumor chemoresistance (Kim et al., 2001; Liu et al., 2002; Shin et al., 2002b; Yang, 2002) , whereas inactivation of Apaf-1 has been observed in malignant melanomas (Soengas et al., 2001) .
While the activation or lack of caspases have been detected in many pathological conditions, it remains to be tested in the majority of the cases mentioned above whether caspases play an indispensable role in these diseases. Due to the potential redundancy in apoptosis pathways and, in many cases, persistence of the cellular dysfunction, we urge caution when considering caspases as therapeutic targets.
Conclusions
In the past decade, the number of publications on caspases has snowballed from zero to more than 10 000. The critical roles of caspases in regulating signaling and execution of apoptosis are well accepted. However, many important questions still remain unanswered. Firstly, it is very likely that we have uncovered only a small fraction of the biological functions of caspases. While the role of caspases in regulating apoptosis is unequivocal, nonapoptotic functions have been demonstrated only for caspase-1, -3, -5, -8, -11 and -14 thus far. It is possible that all caspases will be found to regulate functions other than apoptosis. Secondly, there is still much to be learned about the mechanism of caspase activation initiated by different signaling processes. The DISC and apoptosome complexes provide the prototypic examples of such mechanisms, but the activation mechanisms for other initiator caspases remain to be explored. Thirdly, although the functional roles of caspases in regulating a variety of pathological processes have been demonstrated using cell culture and animal models, the functional roles of caspases in human diseases remain to be examined directly by specific small molecule inhibitors. We are optimistic that a decade from now, we will have caspase inhibitors as therapies for human diseases.
